London · Delayed Price · Currency is GBP · Price in USD Altair Engineering Statistics
Total Valuation
10x Genomics has a market cap or net worth of GBP 1.17 billion. The enterprise value is 906.17 million.
| Market Cap | 1.17B |
| Enterprise Value | 906.17M |
Important Dates
The last earnings date was Wednesday, August 6, 2025.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 111.09M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.95% |
| Shares Change (QoQ) | +1.55% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 109.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.50 |
| PB Ratio | 2.08 |
| P/TBV Ratio | 2.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -14.67 |
| EV / Sales | 1.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.84, with a Debt / Equity ratio of 0.11.
| Current Ratio | 5.84 |
| Quick Ratio | 5.05 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -29,661.14 |
Financial Efficiency
Return on equity (ROE) is -11.30% and return on invested capital (ROIC) is -11.08%.
| Return on Equity (ROE) | -11.30% |
| Return on Assets (ROA) | -9.71% |
| Return on Invested Capital (ROIC) | -11.08% |
| Return on Capital Employed (ROCE) | -17.09% |
| Revenue Per Employee | 360,181 |
| Profits Per Employee | -47,282 |
| Employee Count | 1,306 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 2.50 |
Taxes
In the past 12 months, 10x Genomics has paid 3.85 million in taxes.
| Income Tax | 3.85M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.20% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -34.20% |
| 50-Day Moving Average | 11.72 |
| 200-Day Moving Average | 12.26 |
| Relative Strength Index (RSI) | 48.76 |
| Average Volume (20 Days) | 4,365 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, 10x Genomics had revenue of GBP 470.40 million and -61.75 million in losses. Loss per share was -0.50.
| Revenue | 470.40M |
| Gross Profit | 327.12M |
| Operating Income | -108.26M |
| Pretax Income | -57.90M |
| Net Income | -61.75M |
| EBITDA | -83.62M |
| EBIT | -108.26M |
| Loss Per Share | -0.50 |
Balance Sheet
The company has 326.46 million in cash and 63.31 million in debt, giving a net cash position of 263.14 million.
| Cash & Cash Equivalents | 326.46M |
| Total Debt | 63.31M |
| Net Cash | 263.14M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 564.42M |
| Book Value Per Share | 4.56 |
| Working Capital | 396.66M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 69.54%, with operating and profit margins of -23.02% and -13.13%.
| Gross Margin | 69.54% |
| Operating Margin | -23.02% |
| Pretax Margin | -12.31% |
| Profit Margin | -13.13% |
| EBITDA Margin | -17.78% |
| EBIT Margin | -23.02% |
| FCF Margin | n/a |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.95% |
| Shareholder Yield | n/a |
| Earnings Yield | -5.26% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |